Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONL1204 in progressing open angle glaucoma
NCT05160805Phase 1Completed
- Sponsor
- ONL Therapeutics
- Start
- May 2022
- Primary completion
- Apr 2024
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial of xelafaslatide in open-angle glaucoma (OAG) (3 arms), sponsored by ONL Therapeutics. Primary endpoint: Safety and Tolerability of ONL1204 at 39 weeks. Started May 2022; status: completed.
02
Drugs
xelafaslatide
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT05160805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05160805.